×

A physiologically-based pharmacokinetic model for the antibiotic ertapenem. (English) Zbl 1326.92031

Summary: Ertapenem is an antibiotic commonly used to treat a broad spectrum of infections, which is part of a broader class of antibiotics called carbapenem. Unlike other carbapenems, ertapenem has a longer half-life and thus only has to be administered once a day. A physiologically-based pharmacokinetic (PBPK) model was developed to investigate the uptake, distribution, and elimination of ertapenem following a single one gram dose. PBPK modeling incorporates known physiological parameters such as body weight, organ volumes, and blood flow rates in particular tissues. Furthermore, ertapenem is highly bound in human blood plasma; therefore, nonlinear binding is incorporated in the model since only the free portion of the drug can saturate tissues and, hence, is the only portion of the drug considered to be medicinally effective. Parameters in the model were estimated using a least squares inverse problem formulation with published data for blood concentrations of ertapenem for normal height, normal weight males. Finally, an uncertainty analysis of the parameter estimation and model predictions is presented.

MSC:

92C45 Kinetics in biochemical problems (pharmacokinetics, enzyme kinetics, etc.)
34A35 Ordinary differential equations of infinite order
65L09 Numerical solution of inverse problems involving ordinary differential equations

Software:

DAISY; Matlab
Full Text: DOI

References:

[1] H. T. Banks, <em>Modeling and Inverse Problems in the Presence of Uncertainty</em>,, CRC Press (2014) · Zbl 1296.00029
[2] G. Bellu, Daisy: A new software tool to test global identifiability of biological and physiological systems,, Comput. Meth. Prog. Bio., 88, 52 (2007) · doi:10.1016/j.cmpb.2007.07.002
[3] H. J. Clewell III, Physiologically based pharmacokinetic modeling,, in Preclinical Development Handbook: ADME Biopharmaceutical Properties (ed. S. C. Gad), 1167 (2008)
[4] C. Cobelli, Parameter and structural identifiability concepts and ambiguities: A critical review and analysis,, Am. J. Physiol. - Reg. I., 239 (1980)
[5] G. de Simone, Stroke volume and cardiac output in normotensive children and adults: assessment of relations with body size and impact of overweight,, Circulation, 95, 1837 (1997) · doi:10.1161/01.CIR.95.7.1837
[6] N. C. for Biotechnology Information, Ertapenem,, <a href=
[7] D. Frasca, Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients,, Antimicrob. Agents Chemother., 54, 924 (2010) · doi:10.1128/AAC.00836-09
[8] P. C. Fuchs, In vitro activities of ertapenem (mk-0826) against clinical bacterial isolates from 11 north american medical centers,, Antimicrob. Agents Ch., 45, 1915 (2001) · doi:10.1128/AAC.45.6.1915-1918.2001
[9] ILSI, <em>Physiological Parameter Values for PBPK Models</em>,, International Life Sciences Institute (1994)
[10] M. C. Inc., Highlights of prescribing information,, Invanz® (ertapenem for injection) (2012)
[11] W. Jusko, Pharmacokinetics of capacity-limited systems,, Journal of Clinical Pharmacology, 29, 488 (1989) · doi:10.1002/j.1552-4604.1989.tb03369.x
[12] G. M. Keating, Ertapenem: A review of its use in the treatment of bacterial infections,, Drugs, 65, 2151 (2005) · doi:10.2165/00003495-200565150-00013
[13] H. Kvist, Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations.,, Am. J. Clin. Nutr., 48, 1351 (1988)
[14] D. M. Livermore, Properties and potential of ertapenem,, J. Antimicrob. Chemoth., 52, 331 (2003) · doi:10.1093/jac/dkg375
[15] A. K. Majumdar, Pharmacokinetics of ertapenem in healthy young volunteers,, American Society for Microbiology, 46, 3506 (2002) · doi:10.1128/AAC.46.11.3506-3511.2002
[16] MATLAB, <em>version 7.13.0.564 (R2011b)</em>,, The MathWorks Inc. (2011)
[17] D. Nix, Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians,, J. Antimicrob. Chemoth., 53 (2004) · doi:10.1093/jac/dkh205
[18] S. Pilari, Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models,, J. Pharmacokinet. Phar., 37, 365 (2010) · doi:10.1007/s10928-010-9165-1
[19] D. Plowchalk, Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: A biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds,, Toxicol. Sci., 69, 60 (2002) · doi:10.1093/toxsci/69.1.60
[20] P. Poulin, An algorithm for predicting tissue:blood partition coefficients of organic chemicals from n-octanol:water partition coefficient data,, J. Toxicol. Env. Health, 46, 117 (1995)
[21] P. Poulin, A biologically-based algorithm for predicting human tissue: Blood partition coefficients of organic chemicals,, Human and Experimental Toxicology, 14, 273 (1995)
[22] P. Price, Modeling interindividual variation in physiological factors used in PBPK models of humans,, Crit. Rev. Toxicol., 33, 469 (2003)
[23] P. M. Shah, Ertapenem, the first of a new group of carbapenems,, J. Antimicrob. Chemoth., 52, 538 (2003) · doi:10.1093/jac/dkg404
[24] B. Tummers, Datathief iii,, <a href=
[25] J. Verbraecken, Body surface area in normal-weight, overweight, and obese adults: A comparison study,, Metabolis., 55, 515 (2006) · doi:10.1016/j.metabol.2005.11.004
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.